Literature DB >> 17618943

Plasma adiponectin concentrations and correlates in African Americans in the Hypertension Genetic Epidemiology Network (HyperGEN) study.

James M Shikany1, Cora E Lewis, Barry I Freedman, Donna K Arnett, Catherine Leiendecker-Foster, Tamekia L Jones, David T Redden, Albert Oberman.   

Abstract

Adiponectin has demonstrated insulin-sensitizing, antiatherogenic, and anti-inflammatory properties, and may be an important risk factor for coronary heart disease and diabetes. Relatively few previous studies of plasma adiponectin have included sizable numbers of African Americans. The objective of the study was to investigate plasma concentrations of adiponectin and correlates of these concentrations in African Americans. This was a cross-sectional analysis that took place within the Hypertension Genetic Epidemiology Network. This study included 211 normotensive offspring (aged 22-37 years) of hypertensive siblings recruited by the Hypertension Genetic Epidemiology Network Birmingham, AL, field center. In addition to measuring plasma adiponectin, demographic and lifestyle data were collected, and anthropometric, clinical, and laboratory measurements were obtained. Mean plasma adiponectin concentration was 5.5+/-3.8 microg/mL. Adiponectin was 55% higher in women than in men: 6.5+/-4.4 vs 4.2+/-2.5 microg/mL, respectively (P<.0001). In a multivariable analysis, high-density lipoprotein cholesterol concentration was positively associated and male sex and insulin concentration were negatively associated with plasma adiponectin concentration. Plasma adiponectin concentrations in these African Americans were lower than those reported in other racial/ethnic groups, including Japanese, whites, and Pima Indians. The directions of the associations of plasma adiponectin with other factors were in agreement with results in other racial/ethnic groups.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17618943     DOI: 10.1016/j.metabol.2007.03.020

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  7 in total

1.  Circulating adiponectin is associated with obesity and serum lipids in West Africans.

Authors:  Katherine G Meilleur; Ayo Doumatey; Hanxia Huang; Bashira Charles; Guanjie Chen; Jie Zhou; Daniel Shriner; Adebowale Adeyemo; Charles Rotimi
Journal:  J Clin Endocrinol Metab       Date:  2010-04-09       Impact factor: 5.958

2.  Development of metabolic syndrome in high-sucrose diet fed rats is not associated with decrease in adiponectin levels.

Authors:  M Aslam; S V Madhu
Journal:  Endocrine       Date:  2017-09-06       Impact factor: 3.633

3.  Paradoxical Hyperadiponectinemia is Associated With the Metabolically Healthy Obese (MHO) Phenotype in African Americans.

Authors:  Ayo P Doumatey; Amy R Bentley; Jie Zhou; Hanxia Huang; Adebowale Adeyemo; Charles N Rotimi
Journal:  J Endocrinol Metab       Date:  2012-04-01

4.  Serum adiponectin in relation to body mass index and other correlates in black and white women.

Authors:  Sarah S Cohen; Marilie D Gammon; Lisa B Signorello; Kari E North; Ethan M Lange; Jay H Fowke; Margaret K Hargreaves; Qiuyin Cai; Wei Zheng; William J Blot; Charles E Matthews
Journal:  Ann Epidemiol       Date:  2010-12-15       Impact factor: 3.797

5.  Serum ZAG and Adiponectin Levels Were Closely Related to Obesity and the Metabolically Abnormal Phenotype in Chinese Population.

Authors:  Meijuan Liu; Kun Zhang; Linjie Wang; Hongbo Yang; Kemin Yan; Hui Pan; Huijuan Zhu; Fengying Gong
Journal:  Diabetes Metab Syndr Obes       Date:  2020-08-26       Impact factor: 3.168

6.  Vitamin D and Parathyroid Hormone Relationships with Urinary Nitric Oxide Metabolites and Plasma Isoprostanes in African-Americans.

Authors:  Anna Liza Valiña-Tóth; Zongshan Lai; Shilling Zhang; John M Flack
Journal:  Cardiorenal Med       Date:  2012-07-24       Impact factor: 2.041

7.  Association of adiponectin gene polymorphisms with type 2 diabetes in an African American population enriched for nephropathy.

Authors:  Meredith A Bostrom; Barry I Freedman; Carl D Langefeld; Lingyi Liu; Pamela J Hicks; Donald W Bowden
Journal:  Diabetes       Date:  2008-12-03       Impact factor: 9.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.